Tesidolumab

DB11926InvestigationalProtein Based Therapies

Tesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others.

Mechanism: Pharmacologically active on Complement C5
Curator reviewed
Code names: LFG316

Resolves to

Compound

UNII3FO6689MSDCAS1531594-08-7

Targets

P01031C5

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tesidolumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account